Search Results - "Dumortier, T"

Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4–5 December 2014) by Musuamba, FT, Manolis, E, Holford, N, Cheung, SYA, Friberg, LE, Ogungbenro, K, Posch, M, Yates, JWT, Berry, S, Thomas, N, Corriol‐Rohou, S, Bornkamp, B, Bretz, F, Hooker, AC, Van der Graaf, PH, Standing, JF, Hay, J, Cole, S, Gigante, V, Karlsson, K, Dumortier, T, Benda, N, Serone, F, Das, S, Brochot, A, Ehmann, F, Hemmings, R, Rusten, I Skottheim

“…Inadequate dose selection for confirmatory trials is currently still one of the most challenging issues in drug development, as illustrated by high rates of…”
Get full text

Estimating the contribution of everolimus to immunosuppressive efficacy when combined with tacrolimus in liver transplantation: A model-based approach by Dumortier, T, Looby, M, Luttringer, O, Heimann, G, Klupp, J, Junge, G, Witte, S, VanValen, R, Stanski, D

“…Determining the efficacy contribution of an investigational drug as part of a novel combination regimen that also includes a previously untested dose of a…”
Get full text

mTOR Inhibition in Liver Transplantation: How to Dose for Effective/Safe CNI Reduction? by Junge, G, Dumortier, T, Schwende, H, Fung, J

“…Abstract Everolimus (EVR) is a semi-synthetic mammalian target of rapamycin inhibitor currently under development for liver transplantation (LTx) in…”
Get full text

Deferasirox does not induce QT/QTc-prolongation in healthy subjects by Sechaud, R, Dumortier, T, Balez, S

“…The International Conference on Harmonization (ICH) E14 guidance recommends that almost all drugs should undergo careful clinical testing in a thorough QT/QTc…”
Get full text

Relative bioavailability of deferasirox tablets administered without dispersion and dispersed in various drinks by Séchaud, R, Dutreix, C, Balez, S, Pommier, F, Dumortier, T, Morisson, S, Brun, E

“…Deferasirox (ExjadeA, ICL670) is a new, once-daily oral iron chelator, recently approved as first-line therapy in the treatment of iron overload resulting from…”
Get full text

Results of the first-in-man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients by Winblad, Bengt G, Minthon, L, Floesser, A, Imbert, G, Dumortier, T, He, Y, Maguire, P, Karlsson, M, Östlund, H, Lundmark, J, Orgogozo, J.M, Graf, A, Andreasen, N

Get full text

Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study by Winblad, Bengt, Prof, Andreasen, Niels, MD, Minthon, Lennart, Prof, Floesser, Annette, MSc, Imbert, Georges, PhD, Dumortier, Thomas, MSc, Maguire, R Paul, PhD, Blennow, Kaj, MD, Lundmark, Joens, MD, Staufenbiel, Matthias, PhD, Orgogozo, Jean-Marc, Prof, Graf, Ana, MD

“…Summary Background Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to slow the progression of Alzheimer's disease. We aimed to…”
Get full text

mTOR Inhibition in Liver Transplantation: How to Dose for Effective/Safe CNI Reduction?: 1562 by Junge, G., Dumortier, T., Schwende, H., Fung, J.

Get full text

Orthotopic Liver Transplantation for Idiopathic Portal Hypertension: Indications and Outcome by DUMORTIER, J, BIZOLLON, T, TREPO, C, SCOAZEC, J.-Y, CHEVALLIER, M, BANCEL, B, BERGER, F, DUCERF, C, CLAUDEL-BONVOISIN, S, PALIARD, P, BOILLOT, O

“…Background: Idiopathic portal hypertension is a rare clinical syndrome which may be associated with a spectrum of histological lesions, including nodular…”
Get full text

NVP-AEB071 MAXIMUM TOLERATED DOSE: SAFETY AND TOLERABILITY OF A NOVEL T-CELL ACTIVATION INHIBITOR: 1216 by Slade, A, Jung, T, Dumortier, T, Stingl, G, Seiberling, M, Wilmer, J, Schmouder, R

Get full text

NVP-AEB071: EFFECT OF MILD AND MODERATE HEPATIC IMPAIRMENT ON AEB071 PHARMACOKINETICS: 1215 by Slade, A, Liu, C, Kovarik, J M., Dumortier, T, Preston, R, Schmouder, R

Get full text

O2‐05‐05: Results of the first‐in‐man study with the active Aβ Immunotherapy CAD106 in Alzheimer patients by Winblad, Bengt G., Minthon, L., Floesser, A., Imbert, G., Dumortier, T., He, Y., Maguire, P., Karlsson, M., östlund, H., Lundmark, J., Orgogozo, J.M., Graf, A., Andreasen, N.

Get full text

Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension by Manolis, Athanasios J, Grossman, Ehud, Jelakovic, Bojan, Jacovides, Andrew, Bernhardi, David C, Cabrera, Walter J, Watanabe, Luis A, Barragan, Jaime, Matadamas, Norberto, Mendiola, Alfred, Woo, K.S, Zhu, Jun R, Mejia, Agnes D, Bunt, Ton, Dumortier, Thomas, Smith, Ronald D

“…Objective: The goal of this multicenter, double-blind, randomized, parallel-group study was to compare the effects of losartan potassium (hereafter referred to…”
Get full text

LOSARTAN AND CANDESARTAN PRODUCE COMPARABLE BLOOD PRESSURE REDUCTIONS BUT ONLY LOSARTAN LOWERS PLASMA URIC ACID IN HYPERTENSIVE PATIENTS: P2.40 by Mejia, A., Jacovides, A., Bernhardi, D. C., Cabrera, W. J., Watanabe, L. A., Barragan, J., Matadamas, N., Mendiola, A., Woo, K. S., Jelakovic, B., Grossman, E., Manolis, A., Dumortier, T., Smith, R. D.

Get full text

Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators by Manolis, A J, Grossman, E, Jelakovic, B, Jacovides, A, Bernhardi, D C, Cabrera, W J, Watanabe, L A, Barragan, J, Matadamas, N, Mendiola, A, Woo, K S, Zhu, J R, Mejia, A D, Bunt, T, Dumortier, T, Smith, R D

“…The goal of this multicenter, double-blind, randomized, parallel-group study was to compare the effects of losartan potassium (hereafter referred to as…”
Get full text

Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan by MONTERROSO, V. H, RODRIGUEZ CHAVEZ, V, MIDDLEMOST, S. J, DUMORTIER, T, BUNT, A. M. G, SMITH, R. D, CARBAJAL, E. T, VOGEL, D. R, MARTINEZ, G. J. A, GARCIA, L. H, CUEVAS, J. H. B, TERAN, J. L, HITZENBERGER, G, NEVES, P. L

Get full text

Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies by Naidoo, D P, Sareli, P, Marin, F, Aroca-Martinez, G, Maritz, F J, Jardim, P C, Guerrero, A A, Thompson, C A, Bero, T, Drazka, J, Kosmalova, V, Dumortier, T, Smith, R D

“…The efficacy and tolerability of losartan 100 mg/hydrochlorothiazide (HCTZ) 25 mg and enalapril 10 mg/HCTZ 25 mg were compared in a double-blind, randomized…”
Get more information

Use of ambulatory blood pressure monitoring to compare antihypertensive efficacy and safety of two angiotensin II receptor antagonists, losartan and valsartan. Losartan Trial Investigators by Monterroso, V H, Rodriguez Chavez, V, Carbajal, E T, Vogel, D R, Aroca Martinez, G J, Garcia, L H, Cuevas, J H, Lara Teran, J, Hitzenberger, G, Leao Neves, P, Middlemost, S J, Dumortier, T, Bunt, A M, Smith, R D

“…The efficacy and safety of losartan and valsartan were evaluated in a multicenter, double-blind, randomized trial in patients with mild to moderate essential…”
Get full text

Plasticity of honeybee castes: occurrence of tergal glands in workers by BILLEN, J. P. J, DUMORTIER, K. T. M, VELTHUIS, H. H. W

Get full text